BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology

BACE1 is the rate-limiting protease in the production of synaptotoxic β-amyloid (Aβ) species and hence one of the prime drug targets for potential therapy of Alzheimer’s disease (AD). However, so far pharmacological BACE1 inhibition failed to rescue the cognitive decline in mild-to-moderate AD patie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Acta Neuropathol
Egile Nagusiak: Peters, Finn, Salihoglu, Hazal, Rodrigues, Eva, Herzog, Etienne, Blume, Tanja, Filser, Severin, Dorostkar, Mario, Shimshek, Derya R., Brose, Nils, Neumann, Ulf, Herms, Jochen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2018
Gaiak:
Original Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5904228/
https://ncbi.nlm.nih.gov/pubmed/29327084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00401-017-1804-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak